Login to Your Account



Tivozanib fails in colorectal cancer; Aveo takes a dive

By Catherine Shaffer
Staff Writer

Friday, December 13, 2013
The hits keep coming for Aveo Pharmaceuticals Inc., as its once-daily VEGF receptor tyrosine kinase inhibitor failed another indication, this time colorectal cancer (CRC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription